Intra-Cellular Therapies: FDA Panel to Review Schizophrenia Treatment NDA

https://www.streetinsider.com/Corporate+News/Intra-Cellular+Therapies+%28ITCI%29+Announces+FDA+Advisory+Committee+Meeting+to+Review+NDA+for+Lumateperone+for+Treatment+of+Schizophrenia+in+Adults/15608389.html

Welltower cut to Market Perform from Outperform by Raymond James

https://www.benzinga.com/stock/WELL/ratings

Teladoc started at Buy by Bank of America

https://www.benzinga.com/stock/TDOC/ratings

Concert upped to Buy from Neutral by Janney

https://www.benzinga.com/stock/CNCE/ratings

Addus target upped to $81 from $75 by Raymond James

Maintains Outperform

https://www.benzinga.com/stock/ADUS/ratings

Abbott target hiked to $91 from $89 by Wells Fargo

Maintains Outperform

https://www.benzinga.com/stock/ABT/ratings

Provention Bio bails on IPO

Citing adverse market conditions, Provention Bio (NASDAQ:PRVB) has terminated its 5.5M-share IPO.

https://seekingalpha.com/news/3471008-provention-bio-bails-ipo